(Total Views: 361)
Posted On: 04/09/2018 4:25:44 PM
Post# of 72446
Response from Leo regarding "Cherry Picking" to WILD_4_IPIX copied from the swamp:
WILD_4_IPIX
Monday, 04/09/18 04:15:32 PM
Re: None
0
Post # of 223680
Response from Leo re: Cherry Picking .... this is Public Information
David,
Please note that Soligenix who showed a negligible reduction in the incidence of SOM in their Phase 2 study is limiting their Phase 3 study to those "Scheduled to receive cisplatin chemotherapy of 80-100 mg/m²” https://www.clinicaltrials.gov/ct2/show/NCT03...amp;rank=2
a 7% relative reduction in the incidence of SOM when compared to placebo (from 74% in the placebo group to 69% in the dusquetide group; Supplemental Table 1). In the 6.0 mg/kg group, the results were inconsistent across outcomes (Supplemental Table 1).
https://www.sciencedirect.com/science/article...&ccp=y
The answer is that this is not cherry picking as this is the population most affected. That is why trials for SOM are usually limited to HNC.
I hope this helps, but I now realize we may need to explain this to shareholders in future releases.
Best wishes,
Leo Ehrlich | CEO |
Innovation Pharmaceuticals Inc.
100 Cummings Center, Suite 151-B Beverly, MA 01915
http://www.iPharminc.com
WILD_4_IPIX
Monday, 04/09/18 04:15:32 PM
Re: None
0
Post # of 223680
Response from Leo re: Cherry Picking .... this is Public Information
David,
Please note that Soligenix who showed a negligible reduction in the incidence of SOM in their Phase 2 study is limiting their Phase 3 study to those "Scheduled to receive cisplatin chemotherapy of 80-100 mg/m²” https://www.clinicaltrials.gov/ct2/show/NCT03...amp;rank=2
a 7% relative reduction in the incidence of SOM when compared to placebo (from 74% in the placebo group to 69% in the dusquetide group; Supplemental Table 1). In the 6.0 mg/kg group, the results were inconsistent across outcomes (Supplemental Table 1).
https://www.sciencedirect.com/science/article...&ccp=y
The answer is that this is not cherry picking as this is the population most affected. That is why trials for SOM are usually limited to HNC.
I hope this helps, but I now realize we may need to explain this to shareholders in future releases.
Best wishes,
Leo Ehrlich | CEO |
Innovation Pharmaceuticals Inc.
100 Cummings Center, Suite 151-B Beverly, MA 01915
http://www.iPharminc.com
(3)
(0)
